- Home
- RBNE vs VBIO Comparison
RBNE vs VBIO Comparison
Compare RBNE & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.36
N/A
Current Price
$2.84
Company Overview
Basic Information| Metric | RBNE | VBIO |
|---|---|---|
| Founded | 2024 | N/A |
| Country | Cyprus | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5M | 1.6M |
| IPO Year | 2024 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RBNE | VBIO |
|---|---|---|
| Price | $2.36 | $2.84 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.3K | ★ 507.0K |
| Earning Date | 04-10-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $42.51 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.43 | $0.11 |
| 52 Week High | $8.15 | $4.14 |
Technical Indicators
Market Signals| Indicator | RBNE | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 43.16 | 56.78 |
| Support Level | $2.18 | $2.05 |
| Resistance Level | $3.04 | $4.14 |
| Average True Range (ATR) | 0.23 | 0.46 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 9.30 | 39.37 |
Price Performance
Historical Comparison RBNE
VBIO
About RBNE Robin Energy Ltd.
Robin Energy Ltd is engaged in the ownership and operation of vessels providing seaborne transportation of refined petroleum products and liquefied petroleum gas (LPG). The company operates in two reportable segments: the Tanker segment and the LPG carrier segment.
About VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.